## Abstract Genome‐wide association (GWA) studies require genotyping hundreds of thousands of markers on thousands of subjects, and are expensive at current genotyping costs. To conserve resources, many GWA studies are adopting a staged design in which a proportion of the available samples are geno
Two-Stage sampling designs for gene association studies
✍ Scribed by Duncan Thomas; Rongrong Xie; Mulugeta Gebregziabher
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 211 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0741-0395
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We consider two‐stage case‐control designs for testing associations between single nucleotide polymorphisms (SNPs) and disease, in which a subsample of subjects is used to select a panel of “tagging” SNPs that will be considered in the main study. We propose a pseudolikelihood [Pepe and Flemming, 1991: JASA 86:108–113] that combines the information from both the main study and the substudy to test the association with any polymorphism in the original set. SNP‐tagging [Chapman et al., 2003: Hum Hered 56:18–31] and haplotype‐tagging [Stram et al., 2003a; Hum Hered 55:27–36] approaches are compared. We show that the cost‐efficiency of such a design for estimating the relative risk associated with the causal polymorphism can be considerably better than for a single‐stage design, even if the causal polymorphism is not included in the tag‐SNP set. We also consider the optimal selection of cases and controls in such designs and the relative efficiency for estimating the location of a causal variant in linkage disequilibrium mapping. Nevertheless, as the cost of high‐volume genotyping plummets and haplotype tagging information from the International HapMap project [Gibbs et al., 2003; Nature 426:789–796] rapidly accumulates in public databases, such two‐stage designs may soon become unnecessary. Genet. Epidemiol. © 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract We propose optimized two‐stage designs for genome‐wide case‐control association studies, using a hypothesis testing paradigm. To save genotyping costs, the complete marker set is genotyped in a sub‐sample only (stage I). On stage II, the most promising markers are then genotyped in the
## Abstract The much‐anticipated fixed‐array, genome‐wide SNP genotyping technologies make large‐scale genome‐wide association scans now possible for large numbers of subjects. In this paper we reconsider the problem (Satagopan and Elston [2003] Genet Epidemiol 25:149–157) of optimizing a two‐stage
We propose a cost-effective two-stage approach to investigate gene-disease associations when testing a large number of candidate markers using a case-control design. Under this approach, all the markers are genotyped and tested at stage 1 using a subset of affected cases and unaffected controls, and
## Abstract A two‐stage design is proposed to choose among several experimental treatments and a standard treatment in clinical trials. The first stage employs a selection procedure to select the best treatment, provided it is better than the standard. The second stage tests the hypothesis between